Biomea Fusion, Inc.

Biomea Fusion is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecule therapies, icovamenib and BMF-650, for diabetes and obesity. These programs target metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world’s population. Biomea’s mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity, and related conditions. We aim to cure.

Current securities

1. 424B5 filingSep 22, 2026
2. Other EventsSep 22, 2026
3. 10-Q filingAug 5, 2026
4. Financial Statements and ExhibitsAug 5, 2026
5. Submission of Matters to a Vote of Security HoldersJun 11, 2026